Potassium Chloride
Brand names: 4 Kids Canker Sore Soothing Dots, ALPHA SH, ARNISPORT, AmazaPet, Amazapet, Bio-Combination 10, Bio-Combination 13, Bio-Combination 14, Bio-Combination 17, Bio-Combination 22, Bio-Combination 28, Bio-Combination 4, Bio-Combination 5, Bio-Combination 6, Bio-Combination 9, Bioplasma, Cell Salts Combination, DANDRUFF, DIAMITE, DIAMITE 12, ECZEMA, Effervescent Potassium Chloride, Hendel Schuessler Cell Salts, Homeopathic Ear Ache Formula, K-DUR, K-TAB, K-Tab, KALI MURIATICUM, KALIUM MURIATICUM 6X, KLOR-CON, KLOR-CON M, Kali Mur, Kali muriaticum, Klor Con M, Klor-Con, Klor-Con M, Klor-Con M10, Klor-Con M20, Klor-Con Sprinkle, MUCUSgone, Melange combination, Micro-K 10 Extencaps, Micro-K Extencaps, OHM Mucus Relief, Potassium Chloride Extended-Release, Potassium chloride extended release, Rxhomeo Homeopathic Combo, Rxhomeo Homeopathic Combo 19, Rxhomeo Homeopathic Combo 24, Skin Dr, Slow Release CMPK Bolus, Stamina, Thermotabs Buffered Salt Supplement, Tonsin, Umcka Allergy and Sinus, Wellness Earache, Yeast Gard Advanced, Young Adult ClearAc, Potassium chloride, Potassium Chloride, POTASSIUM CHLORIDE, potassium chloride, POTASSIUM CHLORIDE EXTENDED RELEASE, Kali Muriaticum Kit Refill, POKONZA, Potassium Chloride for Oral Solution, POKONZA potassium chloride, Sore Throat 911, D-125
Boxed warning
Highly Concentrated
Warnings
BOXED WARNING: "Because of reports of intestinal and gastric ulceration and bleeding with extended-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations, or for patients in whom these products are not appropriate." Contraindicated in hyperkalemia, which "can produce cardiac arrest," and in conditions predisposing to hyperkalemia; also contraindicated with gastrointestinal obstruction, delayed gastric emptying, or conditions slowing GI transit because of the ulcerogenic potential of concentrated potassium salts. Caution is advised with potassium-sparing diuretics, ACE inhibitors/ARBs, and in renal impairment.
Contraindications
4 CONTRAINDICATIONS Potassium chloride is contraindicated in patients on triamterene and amiloride. Concomitant use with triamterene and amiloride (4)
Overdose
10 OVERDOSAGE 10.1 Symptoms The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, potentially fatal hyperkalemia can result [see CONTRAINDICATIONS and WARNINGS ] . It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). 10.2 Treatment Treatment measures for hyperkalemia include the following: Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties. Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL. Correction of acidosis, if present, with intravenous sodium bicarbonate. Use of exchange resins, hemodialysis or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity. The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.
Drug interactions
7 DRUG INTERACTIONS Triamterene and amiloride: Concomitant use is contraindicated (7.1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.2) Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia (7.3) 7.1 Triamterene or amiloride Use with triamterene or amiloride can produce severe hyperkalemia. Concomitant use is contraindicated [see Contraindications (4) ] . 7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients on concomitant RAAS inhibitors. 7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDS may produce potassium retention by reducing renal synthesis of prostaglandin E and imparing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.
Uses
Extended-release potassium chloride tablets are indicated for "treatment of patients with hypokalemia with or without metabolic alkalosis," including digitalis intoxication and hypokalemic familial periodic paralysis, and for "prevention of hypokalemia" in patients at risk, such as those on digitalis who would be endangered by even transient hypokalemia, or those with inadequate dietary potassium intake.
Dosage forms & strengths
2 DOSAGE AND ADMINISTRATION Monitor serum potassium and adjust dosages accordingly (2.1) If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation (2.1) Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking. (2.1) Treatment of hypokalemia : Doses range from 40 to 100 mEq/day in divided doses. Limit doses to 40 mEq per dose. (2.2) Prevention of hypokalemia : Typical dose is 20 mEq per day. (2.2) 2.1 Administration and Monitoring If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation. Monitoring Monitor serum potassium and adjust dosages accordingly. Monitor serum potassium periodically during maintenance therapy to ensure potassium remains in desired range. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms, and the clinical status of the patient. Correct volume status, acid-base balance, and electrolyte deficits as appropriate. Administration Take potassium chloride extended-release tablets with meals and with a glass of water or other liquid. Do not take potassium chloride extended-release tablets on an empty stomach because of its potential for gastric irritation [see Warnings and Precautions (5.1) ] . Swallow tablets whole without crushing, chewing or sucking. 2.2 Dosing Dosage must be adjusted to the individual needs of each patient. Dosages greater than 40 mEq per day should be divided such that no more than 40 mEq is given in a single dose. Treatment of Hypokalemia: Typical dose range is 40 to 100 mEq per day. Maintenance or Prophylaxis: Typical dose range is 20 mEq per day.
Ingredients
INGREDIENTS ACTIVE Kalium muriaticum 6x, 12x, 30x INACTIVE 20% alcohol in purified water.
INACTIVE 20% alcohol in purified water.
All identified pills
P274
YELLOW ROUND · Potassium Chloride
P451
WHITE OVAL · Potassium Chloride
P452
WHITE OVAL · Potassium Chloride
P469
WHITE OVAL · Potassium Chloride
P532
WHITE CAPSULE · Potassium Chloride
P533
BLUE CAPSULE · Potassium Chloride
P8
BLUE ROUND · Potassium Chloride
PAD 0180
WHITE CAPSULE · Potassium Chloride
2 manufacturers
PAD 0181
WHITE CAPSULE · Potassium Chloride
Q10
WHITE CAPSULE · Potassium Chloride
5 manufacturers
T
WHITE ROUND · Potassium Chloride
Trisoncap 067onbody
WHITE CAPSULE · Potassium Chloride
Trisoncap 066onbody
BLUE CAPSULE · Potassium Chloride
UPSHER SMITH
YELLOW CAPSULE · Potassium Chloride
5 manufacturers
UPSHER SMITH
BLUE CAPSULE · Potassium Chloride
3 manufacturers
US 10
WHITE CAPSULE · Potassium Chloride
US 20
WHITE CAPSULE · Potassium Chloride
2 manufacturers
US 20
WHITE CAPSULE · Potassium Chloride
US 10
WHITE CAPSULE · Potassium Chloride
2 manufacturers
US 20
WHITE OVAL · Potassium Chloride
10 manufacturers
US 10
WHITE OVAL · Potassium Chloride
6 manufacturers
USL 10
WHITE ROUND · Potassium Chloride
20 manufacturers
USL 8
BLUE ROUND · Potassium Chloride
7 manufacturers
W 1714
WHITE OVAL · Potassium Chloride
W 1715
WHITE OVAL · Potassium Chloride
YH 106
WHITE ROUND · Potassium Chloride
YH 105
WHITE ROUND · Potassium Chloride
YH155
WHITE OVAL · Potassium Chloride
YH156
YELLOW OVAL · Potassium Chloride
a KTAB
YELLOW OVAL · Potassium Chloride
17 manufacturers
n10
YELLOW ROUND · Potassium Chloride
n8
BLUE ROUND · Potassium Chloride
none
WHITE ROUND · Potassium Chloride
par C219
WHITE CAPSULE · Potassium Chloride
par C220
BLUE CAPSULE · Potassium Chloride
WHITE CAPSULE · Potassium Chloride
WHITE ROUND · Potassium Chloride
2 manufacturers
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
WHITE ROUND · Potassium Chloride
Side effects
The most common adverse reactions are gastrointestinal, including "nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea" from local GI irritation; skin rash is reported rarely. Serious but uncommon reactions include small bowel ulceration, stenosis, and perforation.